Summary:
The importance of the association between early lymphocyte recovery and outcome has not been well studied in autologous stem cell transplantation (ASCT). In this retrospective study, we analyzed 90 consecutive patients with non-Hodgkin's and Hodgkin's lymphoma who underwent ASCT. Patients were divided into two groups: group 1 with absolute lymphocyte count (ALC) on day +15 below the median of 667/mm3, and group 2 with ALC ⩾667/mm3. The median progression-free survival (PFS), but not overall survival (OS), was significantly longer in group 2 when compared to group 1 (16 months vs not reached P=0.02). Group 2 patients also had significantly shorter hospital stay, received higher CD34+ cell dose, and had shorter time to neutrophil recovery. Multivariate analysis demonstrated day +15 ALC to be an independent prognostic indicator for PFS, but not OS, while CD34+ cell dose and the number of pretransplant treatments were better predictors for both PFS and OS. We conclude that higher day +15 ALC may independently predict better PFS after ASCT for lymphoma patients; however, whether this merely reflects faster overall recovery caused by higher infused CD34+ cell dose and less pretransplant therapy needs further investigation.
Similar content being viewed by others
References
Cabanillas F, Hagemeister FB, Bodey GP et al. IMVP16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood 1982; 60: 693–697.
Cabanillas F, Hagemeister FB, McLaughlin P et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol 1987; 3: 407–412.
Velasquez WS, Cabanillas F, Salvadore P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high dose Ara C and dexamethasone (DHAP). Blood 1988; 71: 117–122.
Philip T, Armitage JO, Spitzer G et al. High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493–1498.
Philip T, Hartman O, Biron P et al. High dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1118–1124.
Philip T, Guglielmi C, Hagenbeek A et al. A prospective randomized study comparing autologous bone marrow transplantation (ABMT) and salvage chemotherapy (DHAP) in sensitive-relapse of non-Hodgkin's lymphoma (NHL): final analysis of the PARMA study. N Engl J Med 1991; 333: 1540–1545.
Bosly A, Coiffier B, Gisselbrecht C et al. For the Groupe d'Etude des Lymphomes Agressifs. Bone marrow transplantation significantly prolongs survival after relapse in aggressive lymphoma patients treated with the LNH84 regimen. J Clin Oncol 1992; 10: 1615–1623.
Powles R, Singhai S, Treleaven J et al. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood 1998; 91: 3481–3486.
Pavletic ZS, Joshi SS, Piruccello SJ et al. Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematological malignancies. Bone Marrow Transplant 1998; 21: 33–41.
Porrata LF, Gertz MA, Inwards DJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma and non-Hodgkin lymphoma. Blood 2001; 98: 579–585.
Sugrue MW, Williams K, Pollock BH et al. Characterization and outcome of ‘hard to mobilize’ lymphoma patients undergoing autologous stem cell transplantation. Leukemia Lymphoma 2000; 39: 509–519.
Barrett AJ, Ringden O, Zhang MJ et al. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood 2000; 95: 3323–3327.
Guillaume T, Rubinstein DB, Symann M et al. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998; 92: 1471–1990.
Storek J, Ferrara S, Ku N et al. B cell reconstitution after human bone marrow transplantation: recapitulation of ontogeny? Bone Marrow Transplant 1993; 12: 387–398.
Bengtsson M, Smedmyr B, Festin R et al. B lymphocyte regeneration in marrow and blood after autologous bone marrow transplantation: Increased numbers of B cells carrying activation and progression markers. Leukemia Res 1989; 13: 791–797.
Small TN, Keever CA, Weiner-Fedus S et al. B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. Blood 1990; 76: 1647–1656.
Leitenberg D, Rappeport JN, Smith BR . B-cell precursor bone marrow reconstitution after bone marrow transplantation. Am J Clin Pathol 1994; 102: 231–236.
Bengtsson M, Totterman TH, Smedmyr B et al. Regeneration of functional and activated NK and T subset cells in the marrow and blood after autologous bone marrow transplantation: a prospective phenotypic study with 2/3 color FACS analysis. Leukemia 1989; 3: 68–75.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gordan, L., Sugrue, M., Lynch, J. et al. Correlation of early lymphocyte recovery and progression-free survival after autologous stem-cell transplant in patients with Hodgkin's and non-Hodgkin's Lymphoma. Bone Marrow Transplant 31, 1009–1013 (2003). https://doi.org/10.1038/sj.bmt.1704050
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1704050
- Springer Nature Limited
Keywords
This article is cited by
-
The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL)
Current Treatment Options in Oncology (2022)
-
Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial
DARU Journal of Pharmaceutical Sciences (2019)
-
Infusion of autograft natural killer cell/CD14+HLA-DRDIM cell ratio predicts survival in lymphoma post autologous stem cell transplantation
Bone Marrow Transplantation (2018)
-
Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective
Bone Marrow Transplantation (2015)
-
Cellular immunotherapy for plasma cell myeloma
Bone Marrow Transplantation (2013)